Comments
American pharmaceutical company, Eli Lilly and Company (“Lilly”) has issued an additional royalty-free, non-exclusive voluntary licence to Natco Pharma - a local pharmaceutical manufacturer of generic medicines to expand the availability of the drug, Baricitinib, used in the treatment of Covid 19.
Lilly received permission on May 3 for restricted emergency use by the Central Drugs Standard Control Organization (CDSCO) for Baricitinib to be used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
It may be recalled that early this month Natco had received an approval from CDSCO under compulsory licence based on emergency use to produce Baricitinib.
Recently, Lilly had also announced the signing of six voluntary licence agreements with Cipla, Lupin, Sun Pharmaceutical Industries, Dr. Reddy’s MSN Laboratories and Torrent Pharmaceuticals, for the access of the Baricitinib drug by people in India.
Related Stories
Covid-19: Shilpa Medicare ties up with Dr Reddy’s for Sputnik V
Targeted production of dual vector vaccine for first 12 months is 50 million doses
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.